CHICAGO, May 3, 2013 /PRNewswire/ -- Positron
Corporation (OTCBB: POSC), a nuclear medicine healthcare company
specializing in the field of cardiac Positron Emission Tomography
(PET) imaging and high tech pharmacy automation, today announced a
co-marketing agreement with Biologics Modular. Biologics
Modular designs and manufacturers modular facilities that serve as
self-contained biorepositories, biomanufacturing suites and
research suites.
"As we look to accelerate PosiRx® adoption to markets both
within and outside of the United
States, this collaboration is an innovative way reach an
expanded targeted audience," stated Positron's Chief Operating
Officer Charles Conroy, RPh,
MBA.
"PosiRx provides its users the ability to create patient
specific unit doses in an ISO Class 5 environment and aids in
compliance with USP 797 regulations. For those customers that need
additional cleanroom capacity, such as pharmacies providing custom
compounding of cancer treatment therapies, Biologics Modular has
the most comprehensive and cost effective solution on the market
today. By decreasing start-up time and reducing operational costs,
the combined solution allows new markets to be serviced sooner, and
more profitably, than previously possible," Conroy added.
"As cost pressures continue to drive the evolution of the U.S.
pharmacy distribution model, providers are looking for new cost
effective and readily implemented ways to service the nuclear
medicine community," stated Clark H. Byrum
Jr., Biologics Modular President and CEO. "By using Biologic
Modular's pre-constructed and pre-tested modular units, our
customers can lower capital expenditures and reduce development
time in comparison to traditional brick and mortar alternatives.
Pairing Biologics Modular's self-contained cleanroom with PosiRx's
pharmacy automation allows our customers to control initial capital
expenditures and ongoing operating costs better than their
competition."
About Positron: Positron Corporation is a nuclear
medicine healthcare company vertically integrating key segments of
nuclear cardiology—providing an end-to-end solution for cardiac
PET. Through proprietary PET imaging systems,
radiopharmaceuticals and radioisotopes solutions, Positron enables
healthcare providers to more accurately diagnose disease and
improve patient outcomes, while practicing cost effective medicine.
Positron's unique products, market position and approach in
securing the supply chain are substantial advantages, further
accelerating the adoption of cardiac PET and growth of nuclear
cardiology. Positron is redefining the industry. More
information about Positron is available at www.positron.com.
About Biologics Modular: Biologics Modular designs,
manufactures, and sells modular facilities to serve as
self-contained biorepositories, biomanufacturing suites, and
research suites to health science service providers, educational
facilities, and pharmaceutical manufacturers. For more information,
please visit www.biologicsmodular.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
SOURCE Positron Corporation